Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial.

Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Catheter Cardiovasc Interv. 2017 Nov 15; 90(6):1016-1026.

View in: PubMed

subject areas

Aged, 80 and over
Aged, 80 and over
Antithrombins
Antithrombins
Aortic Valve
Aortic Valve
Aortic Valve Stenosis
Aortic Valve Stenosis
Cause of Death
Cause of Death
Dose-Response Relationship, Drug
Dose-Response Relationship, Drug
Europe
Europe
Female
Female
Fibrinolytic Agents
Fibrinolytic Agents
Follow-Up Studies
Follow-Up Studies
Heart Valve Prosthesis
Heart Valve Prosthesis
Heparin
Heparin
Hirudins
Hirudins
Humans
Humans
Incidence
Incidence
Infusions, Intravenous
Infusions, Intravenous
Male
Male
Peptide Fragments
Peptide Fragments
Practice Guidelines as Topic
Practice Guidelines as Topic
Prosthesis Design
Prosthesis Design
Recombinant Proteins
Recombinant Proteins
Retrospective Studies
Retrospective Studies
Survival Rate
Survival Rate
Thrombolytic Therapy
Thrombolytic Therapy
Thrombosis
Thrombosis
Time Factors
Time Factors
Transcatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement
Treatment Outcome
Treatment Outcome
United States
United States

authors with profiles

Usman Baber